2022 World Conference on Lung Cancer (ePosters)-EP08.02-155. The Difference in Clinical Outcomes Between Osimertinib and EGFR-TKI plus Anti-angiogenic Agent in EGFR-mutant NSCLC Patients

EP08.02-155. The Difference in Clinical Outcomes Between Osimertinib and EGFR-TKI plus Anti-angiogenic Agent in EGFR-mutant NSCLC Patients

Back to course

Pdf Summary

This study aimed to compare the clinical efficacy of osimertinib versus anti-angiogenic agents combined with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors (EGFR-TKIs) as first-line treatment in advanced and recurrence EGFR-mutant Non-small Cell Lung Cancer (NSCLC) patients. The study was conducted retrospectively at Taichung Veterans General Hospital in Taiwan, enrolling 80 patients with EGFR exon 19 deletion or exon 21 L858R point mutation. Among the patients, 48 received osimertinib and 32 received first-generation or second-generation EGFR-TKIs plus anti-angiogenic agents.<br /><br />The objective response rate (ORR) was 66.7% in the osimertinib group and 75.0% in the combination therapy group. The disease control rate (DCR) was 85.4% in the osimertinib group and 93.6% in the combination therapy group. The median progression-free survival (PFS) was 18.8 months in the osimertinib group and 16.4 months in the combination therapy group. There was no statistically significant difference in overall survival (OS) between the two groups.<br /><br />For patients with brain metastasis, the median PFS was 22.1 months in the osimertinib group and 16.4 months in the combination therapy group. In patients without brain metastasis, the median PFS was 18.1 months in the osimertinib group and 16.2 months in the combination therapy group. No significant difference in PFS was observed between the two treatment groups in both situations.<br /><br />In terms of EGFR mutation subtypes, there was no difference in clinical efficacy between osimertinib and combination therapy for patients with exon 19 deletion or exon 21 L858R point mutation.<br /><br />Overall, the study concluded that both osimertinib and first- or second-generation EGFR-TKIs combined with anti-angiogenic agents provided good clinical outcomes in advanced and recurrence EGFR-mutant NSCLC patients.

Asset Subtitle

Yen Hsiang Huang

Meta Tag

Speaker Yen Hsiang Huang

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

osimertinib

anti-angiogenic agents

EGFR-TKIs

Non-small Cell Lung Cancer

Taiwan

exon 19 deletion

exon 21 L858R

progression-free survival

overall survival

brain metastasis